A prospective analysis of the genotypic diversity and dynamics of the Candida albicans colonizing flora in neutropenic patients with de novo acute leukemia

Haematologica

Volumn 93, Issue 4, 2008, Pages 581-587

  Dalle, Frédéric ^a,b   Lafon, Ingrid ^c   L'Ollivier, Coralie ^a,b   Ferrant, Emmanuelle ^c   Sicard, Pierre ^a   Labruère, Catherine ^d   Jebrane, Ahmed ^d   Laubriet, Aline ^a   Vagner, Odile ^a   Caillot, Denis ^c   Bonnin, Alain ^a,d  

^a HÔPITAL DU BOCAGE   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c Medical University of Dijon   (France)

^d UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Antifungal resistance; Candida albicans; De novo leukemia; Diversity; Microsatellite

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; BETA LACTAM; NYSTATIN; TEICOPLANIN; VANCOMYCIN;

ACUTE LEUKEMIA; ADD ON THERAPY; ADULT; AGED; ARTICLE; CANDIDA ALBICANS; CANDIDEMIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FUNGAL COLONIZATION; FUNGAL STRAIN; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; NONHUMAN;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FEMALE; GENOME, FUNGAL; GENOTYPE; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; NEUTROPENIA; ORGAN SPECIFICITY; PATIENT ISOLATION; SAMPLING STUDIES; VARIATION (GENETICS);

EID: 42149137343     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11882     Document Type: Article

References (40)

1. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37:1172-7.
2. Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005;26:540-7.
3. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239-44.
4. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 2002;40:852-6.
5. Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006;42:244-51.
6. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003;3:685-702.
7. Voss A, Hollis RJ, Pfaller MA, Wenzel RP, Doebbeling BN. Investigation of the sequence of colonization and candidemia in nonneutropenic patients. J Clin Microbiol 1994;32:975-80.
8. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001;33:1959-67.
9. Martino P, Girmenia C, Venditti M, Micozzi A, Santilli S, Burgio VL, et al. Candida colonization and systemic infection in neutropenic patients. A retrospective study. Cancer 1989;64:2030-4.
10. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220:751-8.
11. Marco F, Lockhart SR, Pfaller MA, Pujol C, Rangel-Frausto MS, Wiblin T, et al. Elucidating the origins of nosocomial infections with Candida albicans by DNA fingerprinting with the complex probe Ca3. J Clin Microbiol 1999;37:2817-28.
12. van Belkum A, Melchers W, de Pauw BE, Scherer S, Quint W, Meis JF. Genotypic characterization of sequential Candida albicans isolates from fluconazole-treated neutropenic patients. J Infect Dis 1994;169:1062-70.
13. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91:1068-75.
14. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, D'Antonio D, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med 1994;120:913-8.
15. Casasnovas RO, Caillot D, Solary E, Bonotte B, Chavanet P, Bonin A, et al. Prophylactic fluconazole and Candida krusei infection. N Engl J Med 1992;326:891-2; author reply 892-3.
16. Kontoyiannis DP, Reddy BT, Hanna H, Bodey GP, Tarrand J, Raad II. Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity. Infect Control Hosp Epidemiol 2002;23:542-5.
17. Safdar A, Armstrong D. Prospective evaluation of Candida species colonization in hospitalized cancer patients: impact on short-term survival in recipients of marrow transplantation and patients with hematological malignancies. Bone Marrow Transplant 2002;30:931-5.
18. Lopez J, Pernot C, Aho S, Caillot D, Vagner O, Dalle F, et al. Decrease in Candida albicans strains with reduced susceptibility to fluconazole following changes in prescribing policies. J Hosp Infect 2001;48:122-8.
19. Reynes J, Pujol C, Moreau C, Mallie M, Renaud F, Janbon F, et al. Simultaneous carriage of Candida albicans strains from HIV-infected patients with oral candidiasis: multilocus enzyme electrophoresis analysis. FEMS Microbiol Lett 1996;137:269-73.
20. Lopez-Ribot JL, McAtee RK, Perea S, Kirkpatrick WR, Rinaldi MG, Patterson TF. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1999;43:1621-30.
21. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998;11:382-402.
22. Denning DW, Evans EG, Kibbler CC, Richardson MD, Roberts MM, Rogers TR, et al. Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology. Eur J Clin Microbiol Infect Dis 1997;16:424-36.
23. Dalle F, Franco N, Lopez J, Vagner O, Caillot D, Chavanet P, et al. Comparative genotyping of Candida albicans bloodstream and nonblood-stream isolates at a polymorphic microsatellite locus. J Clin Microbiol 2000;38:4554-9.
24. Botterel F, Desterke C, Costa C, Bretagne S. Analysis of microsatellite markers of Candida albicans used for rapid typing. J Clin Microbiol 2001;39:4076-81.
25. Sampaio P, Gusmao L, Alves C, Pina-Vaz C, Amorim A, Pais C. Highly polymorphic microsatellite for identification of Candida albicans strains. J Clin Microbiol 2003;41:552-7.
26. Stephan F, Bah MS, Desterke C, Rezaiguia-Delclaux S, Foulet F, Duvaldestin P, et al. Molecular diversity and routes of colonization of Candida albicans in a surgical intensive care unit, as studied using microsatellite markers. Clin Infect Dis 2002;35:1477-83.
27. Simpson A. Measurement of diversity. Nature Protocols 1949;163:288.
28. Dalle F, Dumont L, Franco N, Mesmacque D, Caillot D, Bonnin P, et al. Genotyping of Candida albicans oral strains from healthy individuals by polymorphic microsatellite locus analysis. J Clin Microbiol 2003; 41:2203-5.
29. Lass-Florl C, Gunsilius E, Gastl G, Englisch M, Koch G, Ulmer H, et al. Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution. Ann Hematol 2003;82:565-9.
30. Paterson PJ, McWhinney PH, Potter M, Kibbler CC, Prentice HG. The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients. Br J Haematol 2001;112:175-80.
31. Laverdiere M, Rotstein C, Bow EJ, Roberts RS, Ioannou S, Carr D, et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. J Antimicrob Chemother 2000;46:1001-8.
32. Rozenberg-Arska M, Dekker AW, Branger J, Verhoef J. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. J Antimicrob Chemother 1991;27:369-76.
33. Denning DW, Donnelly JP, Hellreigel KP, Ito J, Martino P, van't Wout JW. Antifungal prophylaxis during neutropenia or allogeneic bone marrow transplantation: what is the state of the art? Ad HOC Working Group. Chemotherapy 1992;38(Suppl 1):43-9.
34. Chandra J, Zhou G, Ghannoum MA. Fungal biofilms and antimycotics. Curr Drug Targets 2005;6:887-94.
35. Specchia G, Pastore D, Montagna MT, Carluccio P, Ciuffreda L, Rizzi R, et al. Fungemia in acute leukemia patients: a single institution's experience. New Microbiol 2004;27:407-10.
36. Reuter CW, Morgan MA, Bange FC, Gunzer F, Eder M, Hertenstein B, et al. Candida kefyr as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients. Clin Infect Dis 2005;41:1365-6.
37. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 2003;41:78-83.
38. van Belkum A, Mol W, van Saene R, Ball LM, van Velzen D, Quint W. PCR-mediated genotyping of Candida albicans strains from bone marrow transplant patients. Bone Marrow Transplant 1994;13:811-5.
39. Lockhart SR, Fritch JJ, Meier AS, Schroppel K, Srikantha T, Galask R, et al. Colonizing populations of Candida albicans are clonal in origin but undergo microevolution through C1 fragment reorganization as demonstrated by DNA fingerprinting and C1 sequencing. J Clin Microbiol 1995;33:1501-9.
40. Samaranayake YH, Samaranayake LP, Tsang PC, Wong KH, Yeung KW. Heterogeneity in antifungal susceptibility of clones of Candida albicans isolated on single and sequential visits from a HIV-infected southern Chinese cohort. J Oral Pathol Med 2001;30:336-46.